143 related articles for article (PubMed ID: 3628857)
1. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
[TBL] [Abstract][Full Text] [Related]
2. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
[TBL] [Abstract][Full Text] [Related]
4. Clinical studies with aminoglutethimide in advanced breast carcinoma.
Harvey HA; Lipton A; Santen RJ
Acta Clin Belg Suppl; 1986; 11():29-40. PubMed ID: 3459321
[No Abstract] [Full Text] [Related]
5. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
[TBL] [Abstract][Full Text] [Related]
6. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
Harris AL; Cantwell BM; Carmichael J; Dawes P; Robinson A; Farndon J; Wilson R
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1105-11. PubMed ID: 2759165
[TBL] [Abstract][Full Text] [Related]
8. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
[TBL] [Abstract][Full Text] [Related]
10. [Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand JP; Mathieu A; Tubiana M; Cappelaere P
Acta Clin Belg Suppl; 1986; 11():41-8. PubMed ID: 3521171
[No Abstract] [Full Text] [Related]
11. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
13. Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Harris AL; Cantwell BM; Sainsbury JR; Needham G; Evans RG; Dawes PJ; Wilson R; Farndon J
Breast Cancer Res Treat; 1986; 7 Suppl():S41-4. PubMed ID: 3742063
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
Milsted R; Habeshaw T; Kaye S; Sangster G; Macbeth F; Campbell-Ferguson J; Smith D; Calman K
Cancer Chemother Pharmacol; 1985; 14(3):272-3. PubMed ID: 3888433
[TBL] [Abstract][Full Text] [Related]
17. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
18. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
20. Androgen priming and response to chemotherapy in advanced prostatic cancer.
Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner TJ; Drago J
J Urol; 1986 Dec; 136(6):1242-6. PubMed ID: 3534315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
